www.buynetmeds.com
FDA says the website introduces into interstate commerce unapproved and misbranded semaglutide drug products, including injectable versions.
Register of FDA warning letters issued concerning GLP-1 medications (semaglutide, tirzepatide) (Source: FDA Inspections & Compliance, data through Nov 5, 2026).
Regulatory & Editorial Notice:
This register reproduces official regulatory enforcement records published by the FDA at the time of issuance. Addressed establishments may have since implemented corrective actions or entered compliance agreements with regulatory authorities. For subsequent remedial filings or official closeout letter status, refer directly to FDA.gov.
Verified Warning Letters
Establishments with Full Address
Chronological Coverage
Explore aggregate counts by calendar year, active ingredient, violation categories, and recipient entity type, or download the full open CSV dataset.
FDA says the website introduces into interstate commerce unapproved and misbranded semaglutide drug products, including injectable versions.
FDA says the company's website and X posts made false or misleading claims that its compounded semaglutide and tirzepatide were FDA-approved, well-studied, American made, and farm-to-table, and that product labels suggested RonanRx was the compounder of those drugs "when in fact it is not."
FDA found www.cheapmedicineshop.com introducing unapproved and misbranded injectable semaglutide ("Semanext Injection") into interstate commerce without an approved application or adequate directions for use.
FDA says the website introduced unapproved and misbranded injectable semaglutide (Semanat Injection) into interstate commerce without FDA approval, adequate directions, or required prescription, violating FD&C Act sections 301, 502(f)(1), 503(b)(1), and 505(a).
FDA says the firm compounded semaglutide and tirzepatide products that "appear to be essentially copies" of FDA-approved drugs regularly and in inordinate amounts without valid individualized prescriber determinations, and prepared sterile products under insanitary conditions with significant CGMP violations.
FDA's July 2026 review of texpeptide.com found seven products, including semaglutide, tirzepatide, and retatrutide, to be unapproved new drugs offered without approved applications, violating FD&C Act sections 301(d) and 505(a).
FDA says the website review found Tirzepatide, Semaglutide, Retatrutide, SS-31, PT-141, Tesamorelin, and BIMORELIN marketed as unapproved new drugs with drug-intended labeling; introducing them into interstate commerce violates FD&C Act sections 301(d) and 505(a).
An FDA website review found nine products, including GLP-1 peptides and bacteriostatic water, are unapproved new drugs lacking approved applications; introducing them into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act.
FDA says the firm marketed seven unapproved new drug products, including semaglutide, tirzepatide, and retatrutide peptides, on its website with claims of treating disease and affecting body function, without FDA-approved applications.
FDA found Bac water, GLP-3R (retatrutide), Semaglutide, SS-31, PT-141, and Tesamorelin to be unapproved new drugs marketed without approved applications, citing website labeling claims and interstate commerce violations.
FDA says Evolv GLP-1 Biomimetic contains EV1-Peptide, a new dietary ingredient with inadequate safety information and potential toxicity concerns; FDA deemed it adulterated under section 402(f)(1)(B) despite two NDIN objections.
FDA says the website made false or misleading claims that compounded semaglutide and tirzepatide products were clinically studied, proven to lose weight, and sourced from FDA-approved pharmacies; compounded products are not FDA-approved.
FDA says the website labels pictured compounded semaglutide and tirzepatide as 'altRx' though altRx is not the compounder, and claims such products are 'clinically proven,' implying FDA approval or evaluation they lack.
FDA says the website's compounded semaglutide and tirzepatide labels name Mint Med as compounder when it is not, making the products misbranded under FD&C Act sections 502(a) and 502(bb).
FDA says the website offers compounded semaglutide and tirzepatide labeled "Ezra," falsely suggesting Ezra is the compounder, making the products misbranded under FD&C Act sections 502(a) and 502(bb).
FDA says the website claims compounded semaglutide and tirzepatide products have the "same active ingredient as Ozempic and Mounjaro," implying FDA approval or evaluation for safety and effectiveness, misbranding them under FD&C Act sections 502(a) and 502(bb).
FDA says the website claims compounded semaglutide and tirzepatide products are 'Same ingredient as Ozempic, Rybelsus, Mounjaro,' implying FDA approval or evaluation when compounded drugs are not FDA-approved, misbranding them under FD&C Act sections 502(a) and 502(bb).
FDA says the website labeled compounded semaglutide and tirzepatide products with 'amie,' falsely suggesting Amie is the compounder, and claimed they contain the same active ingredients as Ozempic, Mounjaro, and Wegovy and use FDA-approved active ingredients, though compounded drugs are not FDA-approved.
FDA says the website falsely claimed compounded semaglutide and tirzepatide are FDA-approved, and that compounding pharmacies are FDA-approved or FDA-licensed, misbranding the products.
FDA says the website falsely suggests Eden compounds semaglutide and tirzepatide and claims products come from “FDA-licensed 503(a) outsourcing facilities”; FDA states compounders are not FDA-approved or licensed, causing misbranding.
Chronological index of all 162 verified warning letters issued concerning GLP-1 compounding and promotion.